Researchers have developed antibody-lectin chimeras for glyco-immune checkpoint blockade, a potential new approach to cancer therapy. This method may involve targeting or removing the protective sugar coating on cancer cells, and it could potentially be effective for many types of cancer. The development is seen as a promising advancement in immunotherapy and glycobiology.